期刊文献+

1例食管裂孔疝合并静脉导管感染患者的药学实践

Pharmaceutical Practice for a Patient with Hiatal Hernia Complicating with Venous Catheter-related Infection
原文传递
导出
摘要 目的:为临床决策用药和规避药物不良事件提供参考。方法:临床药师参与1例食管裂孔疝合并静脉导管感染患者会诊,建议拔出久置的外周静脉穿刺置入中心静脉导管(PICC),并重新置管,将抗感染治疗方案调整为万古霉素0.5 g/次,ivgtt,q12h+氟康唑0.2 g,ivgtt,qd(首日0.4 g,ivgtt,qd),并继续头孢哌酮/舒巴坦2 g/次,ivgtt,q8 h联合抗感染。结果:医师采纳临床药师建议,拔出久置的PICC,感染得到有效治疗;患者病情得到了有效控制,感染治愈。结论:临床药师通过药学监护静脉导管感染患者,有助于医师作出正确的用药决策和规避药物不良事件。 OBJECTIVE: To provide reference for clinical desicion, drug use and ADR avoidance. METHODS: Clinical pharmacists participated in the consultations and therapy plan about a patient with hiatal hernia complicating with venous cathe- ter-related infections. Clinical pharmacists suggested pulling out peripherally inserted central catheter (PICC) and placing a cathe- ter again. Anti-infective therapy plan had been adjusted: vancomycin 0.5 g/time, ivgtt, q12 h; fluconazole 0.2 g, ivgtt, qd (0.4 g,ivgtt,qd on the first day), cefoperazone/sulbactam 2 g, ivgtt, q8h. Vancomycin and fluconazole were additionally used for an- ti-infective therapy. RESULTS: Doctors adopted the suggestions of clinical pharmacist, and pulled out PICC; and then the infec- tion of the patient was controlled effectively. Finally, the infection had been cured. CONCLUSIONS: The participation of clinical pharmacists in the consultation contributes to rational drug use, and assists doctors to make the right clinical decisions and avoid adverse drug events.
出处 《中国药房》 CAS 北大核心 2015年第20期2861-2863,共3页 China Pharmacy
关键词 临床药师 静脉导管感染 药学实践 万古霉素 肾功能 Clinical pharmacists Venous catheter-related infection Pharmaceutical practice Vancomycin Renal function
  • 相关文献

参考文献14

  • 1Gahlot R,Nigam C, Kumar V, et al. Catheter-related blood- stream infections[J], lnt J Crit Illn lnj Sci, 2014, 4 (2) : 162.
  • 2Parameswaran R, Sherchan JB, Varma DM, et al. Intravas- cular catheter-related infections in an Indian tertiary care hospital[J]. J lnfect Dev Ctries, 2011,5 (6) : 452.
  • 3Stevens V, Geiger K, Concannon C, et al. Inpatient costs:mortality and 30-day re-admission in patients with cen- tral-line-associated bloodstream in fections[J]. Clin Mi- crobiol lnfect, 2014, 20 ( 5 ) : 318.
  • 4Rosenthal VD, Bijie H, Maki DG, et al. International noso- comial infection control consortium (1NICC) report: data summary of 36 countries: for 2004-2009[J]. Am J Infect Control, 2012,40(5) : 396.
  • 5Tao F, Jiang R, Chen Y, et al. Risk factors for early onset of catheter-related bloodstream infection in an intensive care unit in China: a retrospective study[J]. Med Sci Monit,2015,doi: 10,12659/MSM.892121.
  • 6O' Grady NP, Alexander M, Burns LA, et al. Guidelines for the prevention of intravascular catheter-related infec- tions[J]. Am J Infect Control, 2011, doi: 10,1016/j.ajic,2011. 01.003.
  • 7Parameswaran R, Sherchan JB, Varma DM, et al. Intravas- cular catheter-related infections in an Indian tertiary care hospital[J]. J lnfect Dev Ctries, 2011,5 (6): 452.
  • 8方强.血管内导管相关感染的预防与治疗指南(2007)[J].中国实用外科杂志,2008,28(6):413-421. 被引量:393
  • 9胡付品,朱德妹,汪复,蒋晓飞,孙自镛,陈中举,胡志东,李金,谢轶,康梅,徐英春,张小江,张朝霞,季萍,王传清,王爱敏,倪语星,孙景勇,俞云松,林洁,储云卓,田素飞,徐元宏,沈继录,单斌,杜艳,卓超,苏丹虹,张泓,孔菁,魏莲花,吴玲,胡云建,艾效曼.2013年中国CHINET细菌耐药性监测[J].中国感染与化疗杂志,2014,14(5):365-374. 被引量:622
  • 10卫生部医政司,卫生部合理用药专家委员会.国家抗微生物治疗指南[M],1版.北京:人民卫生出版社,2013:24、224.

二级参考文献17

  • 1Arias CA. Murray BE. Antibiotic-resistant bugs in the 21st century-a clinical super-challenge[J].N Engl J Med. 2009. 360(5): 439-443.
  • 2Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing[S]. Twentyfourth informational supplement. 2014. M100-S24 Vol 34 No. 1.
  • 3Hu F. Chen S. Xu X. et al. Emergence of carbapenem-resistant clinical Enterobacteriaceae isolates from a teaching hospital in Shanghai. China[J]. J Med Microbiol , 2012. 61 (Pr 1): 132- 136.
  • 4Brink AJ. Feldman C. Grolman DC. et al. Appropriate use of the carbapenems[J]. S Afr Med J. 2004. 94 (10 Pt 2): 857-861.
  • 5Chen S. Hu F. Zhang X. et al. Independent emergence of colistin-resistant Enterobacteriaceae clinical isolates without colistin treatrnentj]]. J Clin Microbiol , 2011. 49( 11): 4022- 4023.
  • 6van Duin D. Kaye KS. Neuner EA. et al. Carbapenem-resistant Enterobacteriaceae: a review of treatment and outcomes[J]. Diagn Microbiol Infect Dis. 2013. 75(2): l1S-120.
  • 7Daikos GL. Tsaousi S. Tzouvelekis LS. et al. Carbapenemaseproducing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems [J]. Antimicrob Agents Chernother , 2014.58 (4): 2322-2328.
  • 8Tascini C. Tagliaferri E. Giani T. et al. Synergistic activity of colistin plus rifampin against colistin-resistant KPCproducing Klebsiella pneumoniae [J]. Antimicrob Agents Chernother , 2013. 57 (8): 3990-3993.
  • 9Pulcini C. Bush K. Craig WA. et al. Forgotten Antibiotics: an Inventory in Europe. the United States. Canada. and Australia[J]. Clin Infect Dis. 2012. 54(2): 268-274.
  • 10Falagas ME. Giannopoulou KP. Kokolakis GN. et al. Fosfomycin , use beyond urinary tract and gastrointestinal infections [J]. Clin Infect Dis. 2008. 46(7): 1069-1077.

共引文献1012

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部